MiMedx’s internal probe prompts CEO Petit’s resignation


Parker H. “Pete” Petit has spent years waging court battles and a war of words against those accusing his Marietta-based company of fraud.

The MiMedx CEO and chairman called stories about his company inflating revenues by over-shipping medical products “bogus.” He called the short sellers who accused MiMedx of channel stuffing Veterans Affairs hospitals “wealthy thieves” who can get away with lying because they aren’t held to the same standards as corporate executives. He blamed “rogue” sales people for ongoing investigations by federal agencies.

“This is all stuff trumped up to drive the stock price down,” Petit told The Atlanta Journal-Constitution earlier this year.

VIDEO: Previous VA hospital coverage

But his detractors received more validation on Monday. Following further discoveries in the biopharma company’s own ongoing internal investigation, Petit abruptly stepped down, ending his nine-year run leading what Fortune magazine once ranked the fifth-fastest growing public company, ahead of Facebook Inc. and Amazon.com Inc. On Monday, MiMedx stock dropped 38 percent to $3.93 a share.

Petit, 78, has been among metro Atlanta’s business elite for decades, having started his first company, Healthdyne, Inc., in the early 1970s and establishing a track record of turning health industry startups into billion-dollar companies.

Feisty and politically-connected, he served as Donald Trump’s campaign finance chairman in Georgia and has connections to U.S. Sen. Johnny Isakson and former U.S. Secretary of Health and Human Services Tom Price.

With Petit’s departure came another foreboding sign for the company: Replacing Petit as interim CEO will be David Coles, a senior leader at Alvarez & Marsal who specializes in interim management of under-performing businesses. Coles went to work as CFO of Lehman Brothers Holdings Inc. just days before the global financial services firm filed for bankruptcy in 2008.

The hire shows “that they’re on an express train to Chapter 11,” said Jessica Cino, a Georgia State University law school professor and former white collar criminal defense attorney. MiMedx employs roughly 950 people, more than half of them based in Georgia.

Also out at MiMedx is Petit’s right hand man, Bill Taylor, the company’s president and chief operating officer.

‘Heads have to roll’

A news release Monday indicated Petit’s and Taylor’s departures weren’t voluntary, but “are based on the Board of Directors’ business judgment regarding the company’s leadership and direction, and arise, in part, from information the Audit Committee has identified through its previously announced independent investigation.”

Charles Evans, MiMedx’s lead independent director, has been named chairman of the board, and Petit will remain a board member, the news release said. Petit did not respond to messages from AJC on Monday, nor did MiMedx’s spokesman.

Cino, who as a defense attorney specialized in pharmaceutical companies and banks, said the company could be keeping Petit on the board because of a contractual clause or for insurance purposes. It could also be that they didn’t find him culpable in fraud, but rather responsible for a lack of oversight or zero oversight.

“That itself means heads have to roll,” Cino said.

Fortune magazine described MiMedx as “a designer of a kind of modern medical alchemy.’’ The company sells regenerative injections and wound coverings derived from human placental tissue, used in orthopedic treatments and on burn victims, among other uses.

Since former employees have come forward over the past year with allegations of over-shipping to inflate earnings — known as “channel stuffing” — MiMedx has come under scrutiny from federal investigators. Monday’s news release brought up last year’s subpoena from the U.S. Securities and Exchange Commission, and said the company continues to produce documents in response and that the U.S. Department of Justice is working parallel to the SEC.

MiMedx is also entangled in lawsuits with shareholders and ex-employees who sued under whistleblower laws. The ex-empolyees alleged a fraudulent scheme where MiMedx, with Petit’s knowledge, flooded VA hospitals’ shelves with its EpiFix grafts and booked the revenue even though the hospitals hadn’t ordered them.

The company launched its own internal investigation led by auditing firm KPMG and law firm King & Spalding. Meanwhile, the Department of Veterans Affairs became involved, with three South Carolina VA workers indicted earlier this year for allegedly taking inducements from a MiMedx sales representative in exchange for over-using the company’s product on veterans.

A former account executive for MiMedx, Mary Armstrong, called Petit’s resignation “vindication.” She says that two months after she told him and other executives about overcharging, up-charging and over-shipping at dozens of medical facilities in the Dallas-Fort Worth area, the company fired her for poor sales performance.

“The fact that those two, the most prideful men I’ve ever seen in my life, stepped down, goes to show the amount of nefariousness that has gone on at that company,” said Armstrong, who is not part of any litigation with MiMedx. “But there’s still a long way to go. There are still honest whistleblowers out there who are still being attacked by MiMedx.”

Last month, findings in the internal investigation led the company to announce that its financial statements released from 2012-2016 and the first three quarters of 2017 could not be relied on, and that the company would withdraw all previous financial guidance issued for 2018. At that time, MiMedx parted ways with then-Chief Financial Officer Michael Senken and treasurer John Cranston.

Those developments led short seller Mark Cohodes to predict on his website, PetiteParkerTheBarker.com, that Petit would be out as CEO by July 4 and that MiMedx will declare bankruptcy by Labor Day.

After Monday’s resignations, he adjusted the latter forecast to the end of this month.

“When the CEO, the president and the CFO are all gone – this thing’s a bankruptcy,” he said. “It’s a massive fraud. It’s been a massive lie all the way through.”

Staff Writer Scott Trubey contributed to this article.



Reader Comments ...


Next Up in Business

Is active or passive investing best? You may be surprised
Is active or passive investing best? You may be surprised

It’s hard to believe, but we’re more than halfway through 2018. So far, it’s been a year of market ups and downs. We’ve endured a correction, experienced a rebound, and are now back closer to flat. The recent choppiness makes this a good time to revisit the great debate between active and passive investing. Last year, an email...
Atlanta company eyeing sports betting industry outside Georgia
Atlanta company eyeing sports betting industry outside Georgia

When Inside Injuries launched in 2016, the company was intended to supply fantasy sports players and companies with injury analysis on top players across sports, CEO Tracy Hankin said. Sports betting wasn’t in the company’s sights. A Supreme Court ruling in May, which struck down a federal law outlawing sports betting outside of Nevada...
No, you don’t need a perfect score to be an exceptional borrower

WASHINGTON — I have been told many times that I’m a perfectionist, but I feel that I’m not perfect enough for such a label. Yet it’s true that my life is driven by a relentless report-card-like quest for excellence. This is why I understand people with super-high FICO credit scores who seethe that they have yet to get a perfect...
Man fired after encounter with 'racist' customer. After sharing story, Home Depot offers job back.
Man fired after encounter with 'racist' customer. After sharing story, Home Depot offers job back.

After a man last Thursday approached the checkout at a Home Depot in Albany, New York, staff member Maurice Rucker asked him to leash his dog. That's when the man exploded. » RELATED: Atlanta's Home Depot growing in various ways, but not new stores Rucker, a 60-year-old black man, claimed he was fired Tuesday after defending himself from...
Peach problem: Georgia fruits clobbered again
Peach problem: Georgia fruits clobbered again

Uncooperative weather has taken a jumbo bite out of the Peach State’s peach crop , a second year of pain for growers of the iconic fruit. And similar hardship appears to have eliminated half Georgia’s more lucrative blueberry yield. The difficult years have left Atlanta shoppers in the produce aisle facing the prospect of paying...
More Stories